基线IL-6、IL-8、IFN-ω和perforin作为免疫检查点抑制剂治疗的转移性非小细胞肺癌的预后生物标志物
Baseline IL-6, IL-8, IFN-ω, and perforin as prognostic biomarkers in immune checkpoint inhibitor-treated metastatic non-small cell lung cancer.
肺癌
117 篇文献
8月12日 星期三 · 26 篇
接受亚肺叶切除的肺癌患者住院时间延长的预测因素
Predictors of prolonged hospital stay in patients with lung cancer undergoing sublobar resection.
美国癌症协会国家肺癌圆桌会议战略计划：肺癌护理连续过程中先进影像学的机遇
The American Cancer Society National Lung Cancer Roundtable strategic plan: Opportunities in advanced imaging across the lung cancer care continuum.
整合临床、CT和实验室特征的机器学习诊断模型的开发和验证，以区分孤立性肺结节患者的肺癌和肺结核：一项单中心回顾性研究
Development and validation of machine learning diagnostic models integrating clinical, CT, and laboratory features to differentiate lung cancer from pulmonary tuberculosis in patients with solitary pulmonary nodules: a single-center retrospective study.
新辅助伯福替尼联合伏罗尼布治疗可切除II-IIIB期EGFR突变非小细胞肺癌：一项前瞻性、单臂I/II期试验的研究方案
Neoadjuvant befotertinib plus vorolanib in resectable stage II-IIIB EGFR-mutant NSCLC: a study protocol for the prospective, single-arm phase I/II trial.
诊断时症状与接受手术治疗I期非小细胞肺癌患者预后的关联：一项前瞻性维护登记处的回顾性队列分析
Association of symptoms at diagnosis with prognosis in patients with surgically treated stage I non-small cell lung cancer: a retrospective cohort analysis of a prospectively maintained registry.
肺癌精准医学中的表观遗传学：从实验室到临床——一篇叙述性综述
Epigenetics in lung cancer precision medicine: from bench to bedside-a narrative review.
三级淋巴结构预测III期非小细胞肺癌的新辅助化学免疫治疗反应
Tertiary lymphoid structures predict the neoadjuvant chemoimmunotherapy response of stage III non-small cell lung cancer.
同步放化疗后接受度伐利尤单抗的局限性期小细胞肺癌患者的真实世界分析
Real-world analysis in patients with limited-stage small-cell lung cancer who received durvalumab after concurrent chemoradiotherapy.
FOXA1通过激活Wnt通路驱动小细胞肺癌化疗耐药
FOXA1 drives chemoresistance through activating Wnt pathway in small cell lung cancer.
晚期非小细胞肺癌未知或无可用基因组改变患者的后线治疗模式与结局：中国多中心真实世界研究（RECAP研究）
Treatment patterns and outcomes of later-line therapy in advanced non-small cell lung cancer with unknown or no actionable genomic alterations: a multicenter real-world study in China (RECAP study).
高分辨率解析肺癌：单细胞和空间转录组测序应用的叙述性综述
Deciphering lung cancer at high resolution: a narrative review of applications of single-cell and spatial transcriptomics sequencing.
PGE2介导的NK细胞重编程驱动肺腺癌获得性免疫治疗耐药
PGE2-mediated NK cell reprogramming drives acquired immunotherapy resistance in lung adenocarcinoma.
血清神经元特异性烯醇化酶升高作为小细胞肺癌化疗免疫治疗结局不佳和CD8阳性淋巴细胞浸润减少的指标：一项回顾性队列研究
Elevated serum neuron-specific enolase as an indicator of poor chemo-immunotherapy outcomes and reduced CD8-positive lymphocyte infiltration in small-cell lung cancer: a retrospective cohort study.
MET抑制剂联合EGFR/ALK酪氨酸激酶抑制剂在经治EGFR突变/ALK重排且MET过表达的非小细胞肺癌患者中的有益前景：一项回顾性队列研究
Promising benefits of MET inhibition combined with EGFR/ALK tyrosine kinase inhibitor in heavily treated non-small cell lung cancer patients with EGFR-mutant/ALK rearrangement and MET overexpression: a retrospective cohort study.
将浸润性黏液腺癌纳入IASLC肺腺癌分级系统的回顾性队列研究
A retrospective cohort study integrating invasive mucinous adenocarcinoma into the IASLC grading system for lung adenocarcinoma.
免疫保护性放疗与围手术期免疫治疗在III期非小细胞肺癌中的应用：IIIA/IIIB期非小细胞肺癌当前管理与未来方向的叙述性综述
Immune-preserving radiotherapy and perioperative immunotherapy in stage III NSCLC: a narrative review of current management and future directions for IIIA/IIIB NSCLC.
I-III期非小细胞肺癌中的最佳支持治疗：真实世界研究人群中因放弃根治性治疗原因而异的生存分析
Best supportive care in stage I-III non-small cell lung cancer: survival by reason for curative treatment omission in a real-world study population.
KRAS-G12D突变非小细胞肺癌的靶向治疗策略：叙述性综述
Targeted therapeutic strategies for KRAS-G12D-mutant non-small cell lung cancer: a narrative review.
CT衍生腹部器官体积测量预测切除的非小细胞肺癌的无复发生存和无病生存：多中心回顾性队列研究
CT-derived abdominal organ volumetrics for predicting recurrence-free and disease-free survival in resected non-small cell lung cancer: a multicenter retrospective cohort study.
非小细胞肺癌中模拟芯针活检尺寸下的瘤内免疫异质性：一项探索性研究
Intratumor immune heterogeneity across simulated core biopsy sizes in non-small cell lung cancer: an exploratory study.
VISTA (PD-1H)和PVR (CD155)在非小细胞肺癌中的表达作用与临床意义：一项系统综述
Role and clinical significance of VISTA (PD-1H) and PVR (CD155) expression in non-small cell lung carcinoma: a systematic review.
小细胞肺癌中的多重定量蛋白质组学：DLL3分布的阶段关联性和胸苷磷酸化酶的独立预后信号
Multiplexed quantitative proteomics in small-cell lung cancer: stage-linked DLL3 distribution and an independent prognostic signal of thymidine phosphorylase.
长寿相关的FOXO3基因型减轻戒烟后肺癌风险：一项前瞻性队列研究
Longevity-associated FOXO3 genotype mitigates the risk of lung cancer after smoking cessation: a prospective cohort study.
开发并验证预测肺癌患者对PD-1抑制剂客观反应的机器学习模型
Development and validation of a machine learning model for predicting objective response to PD-1 inhibitors in lung cancer patients.
在癌症预防研究中连接空气污染与肺癌的血浆代谢组学特征
Blood metabolomic signatures linking air pollution to lung cancer in the Cancer Prevention Studies.
8月11日 星期二 · 7 篇
肺癌筛查中偶然发现的结构化分诊：英国项目的结局
Structured triage of incidental findings in lung cancer screening: Outcomes from a UK programme.
肺腺癌进展的高分辨率循环代谢图谱支持早期准确诊断
A high-resolution circulating metabolic atlas of lung adenocarcinoma progression supports early and accurate diagnosis.
对比增强CT影像组学在实性成分占比≥25%的肺腺癌中识别高级别模式及预后分层
Contrast-enhanced CT Radiomics for High-Grade Pattern Identification and Prognostic Stratification in Lung Adenocarcinoma with Consolidation-to-Tumor Ratio of 25% or More.
中央型小尺寸非小细胞肺癌肺段切除术的肿瘤学结局：多中心研究（CReGYT-02研究）
Oncological Outcomes of Segmentectomy for Centrally Located Small-Sized Non-small-cell Lung Cancer: A Multicenter Study (CReGYT-02 Study).
内源性CD155通过PI3K/AKT/HIF-1α-糖酵解轴驱动代谢重编程，介导非小细胞肺癌的抗PD-1耐药
Endogenous CD155 drives metabolic reprogramming via PI3K/AKT/HIF-1α-glycolysis axis to mediate anti-PD-1 resistance in non-small cell lung cancer.
IV期非小细胞肺癌的肺移植——在资源匮乏环境中的一种有前景的干预措施
Lung Transplant for Stage IV NSCLC-A Promising Intervention in a Scarce-Resource Environment.
中国人群水果和蔬菜摄入与肺癌、结直肠癌、胃癌及总体癌症风险的关系：一项前瞻性队列研究
Fruit and Vegetable Intake in Relation to the Risks of Lung, Colorectal, Stomach, and Overall Cancers in China: A Prospective Cohort Study.
8月10日 星期一 · 3 篇
支原体感染通过趋同的转录组重编程驱动非小细胞肺癌的EGFR-TKI耐药
Mycoplasma infection drives EGFR-TKI resistance through convergent transcriptomic reprogramming in non-small cell lung cancer.
奥希替尼联合或不联合化疗治疗伴EGFR及并发TP53突变的晚期非小细胞肺癌：一项随机临床试验
Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.
Christie肺癌症状量表（CSI-Lung）电子患者报告结局测量工具的真实世界评估：效度、信度、反应性和患者体验
Real-world evaluation of the christie symptom inventory-lung cancer (CSI-lung) electronic patient-reported outcome measure: validity, reliability, responsiveness, and patient experiences.
8月9日 星期日 · 4 篇
Li-Fraumeni综合征相关肺癌的临床特征与诊疗管理
Clinical characteristics and management of Li-Fraumeni syndrome-associated lung cancer.
非小细胞肺癌相关胸腔积液的免疫特征及其预后意义
Immune signatures in NSCLC associated pleural effusions and implications for prognosis.
探索PDLIM2作为肺腺癌的预后生物标志物和治疗靶点
Exploring PDLIM2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma.
肺癌患者治疗后影像学检查：在纵向队列中遵守监测指南与生存改善相关
Post-Treatment Imaging in Lung Cancer Patients: Adherence to Surveillance Guidelines Is Associated with Improved Survival in a Longitudinal Cohort.
8月8日 星期六 · 4 篇
肺肉瘤样癌中非经典 MET 外显子 14 剪接位点变异对卡马替尼治疗应答
A Noncanonical MET Exon 14 Splice-Site Variant in Pulmonary Sarcomatoid Carcinoma With Response to Capmatinib.
广泛期小细胞肺癌中，二线化疗的疗效不受既往免疫治疗暴露的影响：来自 ESME 法国国家真实世界队列的结果
Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort.
DAFNet：基于全肺 CT 的多模态深度学习模型用于肺腺癌气腔播散的自动预测
DAFNet: A multi-modal deep learning model based on whole-lung CT for the automated prediction of the air space spread of lung adenocarcinoma.
雪茄、小雪茄和烟斗吸烟对肺癌风险和筛查资格的影响
The effect of cigar, cigarillo and pipe smoking on lung cancer risk and screening eligibility.
8月7日 星期五 · 2 篇
IB期EGFR突变非小细胞肺癌辅助EGFR-TKI降阶梯治疗：一项真实世界研究
De-escalation of Adjuvant EGFR-TKI in Stage IB EGFR-Mutated Non-small-cell Lung Cancer: A Real-World Study.
基于必需性驱动的临床前和临床背景下抗癌药物反应预测
Essentiality-driven prediction of anticancer drug responses in preclinical and clinical contexts.
8月6日 星期四 · 9 篇
CHIO3：化疗联合免疫检查点抑制剂治疗可手术的 IIIA/B 期（N2）非小细胞肺癌：手术结果
CHIO3: CHemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B (N2) Non-Small Cell Lung Cancer: Surgical Outcomes.
NCCRP1 缺失克服肺腺癌的免疫逃逸
Loss of NCCRP1 overcomes immune evasion in lung adenocarcinoma.
不吸烟肺癌中协调的微生物-炎症关联
Coordinated microbial-inflammatory associations in never-smoking lung cancer.
M1C 是对 KRAS 抑制剂耐药的 NSCLC KRAS G12C 突变肿瘤的可成药靶标
M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors.
FDG PET-CT 对部分实性肺腺癌淋巴结分期的系统综述和 Meta 分析
Systematic review and meta-analysis of FDG PET-CT for nodal staging of part-solid lung adenocarcinomas.
退伍军人健康管理局中非小细胞肺癌新辅助化疗免疫治疗后的退出
Dropout after Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer in the Veterans Health Administration.
糖尿病增加转移性非小细胞肺癌免疫治疗相关毒性但不影响疗效：一项多中心回顾性研究
Diabetes Increases Immunotherapy-Related Toxicity but Not Efficacy in Metastatic Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.
运动调节 NSCLC 和非荷瘤肺中肥胖诱导的免疫功能障碍：对肺癌治疗和拦截的意义
Exercise Modulates Adiposity-induced Immune Dysfunction in NSCLC and Non-tumor-Bearing Lungs: Implications for Lung Cancer Therapy and Interception.
RanBP2通过LRSAM1 SUMO化和泛素化稳定SLC7A1，促进铁死亡抵抗并损害肺腺癌的治疗反应
RanBP2 promotes ferroptosis resistance and compromises therapeutic response by stabilizing SLC7A1 through LRSAM1 SUMOylation and ubiquitination in lung adenocarcinoma.
8月5日 星期三 · 6 篇
提升肺癌免疫治疗后静脉血栓栓塞风险预测
Enhancing venous thromboembolism risk prediction after immunotherapy for lung cancer.
AI生物学家XunZi揭示疾病修饰靶点
XunZi, an AI biologist, reveals disease-modifying targets.
RAB32-USP13轴促进TOM40线粒体定位以驱动非小细胞肺癌进展
The RAB32-USP13 axis facilitates TOM40 mitochondrial localization to promote non-small cell lung cancer progression.
阿美替尼与奥希替尼一线治疗EGFR突变非小细胞肺癌：一项回顾性真实世界多中心研究
Aumolertinib Versus Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Multicenter Study.
探讨染色体外DNA在肺癌中的作用
Examining the role of extrachromosomal DNA in lung cancer.
CHAF1A促进RAD51装载和同源重组以驱动肿瘤放射抗性
CHAF1A promotes RAD51 loading and homologous recombination to drive tumor radioresistance.
8月4日 星期二 · 4 篇
人源化小鼠揭示小细胞肺癌对免疫-放疗联合治疗的 T 细胞浸润表型
SCLC humanized mice identify T cell infiltration phenotypes in response to combination immune-radiation therapies.
BRAF 融合定义了非小细胞肺癌的治疗脆弱性和酪氨酸激酶抑制剂耐药
BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer.
新辅助化学免疫治疗后肺癌中肿瘤远端纵隔淋巴结含有肿瘤相关祖细胞耗竭 T 细胞
Tumor-distal mediastinal lymph nodes harbor tumor-related progenitor exhausted T cells in lung cancer after neoadjuvant chemoimmunotherapy.
利用 Stereo-XCR-seq 揭示肺腺癌中肿瘤反应性淋巴细胞引发的异位类生发中心生态位
Uncovering ectopic GC-like niches for tumor reactive lymphocyte priming in lung adenocarcinoma using Stereo-XCR-seq.
8月2日 星期日 · 3 篇
转移性非小细胞肺癌患者临终前使用全身抗癌治疗的相关因素：一项多中心回顾性队列研究
Associated factors regarding systemic anticancer therapy use prior to death among patients with metastatic non-small cell lung cancer: A multicentre retrospective cohort study.
PER1相关炎症信号通路介导夜班暴露对煤矿工人肺功能降低的影响
PER1-related inflammatory signaling links night shift exposure to lower lung function in coal miners.
早期非小细胞肺癌汇总证据的局限：我们是在比较治疗还是患者？
The limits of pooled evidence in early-stage NSCLC: are we comparing treatments or patients?
8月1日 星期六 · 2 篇
7月31日 星期五 · 3 篇
Taletrectinib 与第一代 TKI 在未接受过 TKI 治疗的 ROS1+ 非小细胞肺癌中的疗效比较：一项匹配调整间接比较
Comparative efficacy of taletrectinib versus first-generation TKIs in TKI-naïve ROS1+ non-small cell lung cancer: A matching-adjusted indirect comparison.
免疫检查点抑制剂在乙肝表面抗原阳性肺癌患者中的疗效与安全性：一项真实世界队列研究
Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study.
联合循环肿瘤抗原模型在一线治疗非小细胞肺癌中展现额外的预后价值
Combined circulating tumor antigen model demonstrates additional prognostic value in first-line treatment of non-small cell lung cancer.
7月30日 星期四 · 7 篇
ctDNA检测Adagrasib治疗NSCLC中的多克隆KRAS耐药
ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib-Treated NSCLC.
最优肺癌 CT 筛查策略:纳入 NELSON 证据、不断变化的治疗成本与戒烟干预的成本效益研究
The Optimal Lung Cancer Ct Screening Strategy: A Cost-Effectiveness Study Incorporating Nelson Evidence, Evolving Cost of Treatment and Smoking Cessation Interventions.
同一诊断,不同疾病:为何性别在肺癌中至关重要
Same Diagnosis, Different Disease: Why Sex Matters in Lung Cancer.
HERC4与USP16协同通过稳定RPS15增强蛋白翻译以促进肺腺癌生长
HERC4 synergizes with USP16 to promote lung adenocarcinoma growth by augmenting protein translation via stabilizing RPS15.
双靶向BCL-XL与MCL-1揭示非小细胞肺癌中一种快速且可利用的凋亡缺陷
Dual targeting of BCL-XL and MCL-1 exposes a rapid and exploitable apoptotic vulnerability in non-small cell lung cancer.
全国范围内实施可切除NSCLC新辅助nivolumab为基础的化疗-免疫治疗:一项前瞻性多中心研究的手术结果
Nationwide Implementation of Neoadjuvant Nivolumab-Based Chemo-Immunotherapy for Resectable NSCLC: Surgical Outcomes from a Prospective Multicenter Study.
EHR提醒纠正吸烟史对肺癌筛查的影响:一项随机对照质量改进研究
The Impact of EHR Alerts to Correct Smoking History on Lung Cancer Screening: A Randomized Controlled Quality Improvement Initiative.
7月29日 星期三 · 5 篇
评估健康相关生活质量问卷在非小细胞肺癌常见症状性不良事件中的捕获能力
Evaluating health-related quality of life questionnaires in capturing common symptomatic adverse events in non-small cell lung cancer.
基于呼气组学的肺癌分诊工具开发与多中心验证:一项 5,214 例参与者的前瞻性研究
Development and Multi-center Validation of a Breathomics-Based Triage Tool for Lung Cancer: A Prospective Study of 5,214 Participants.
美国当前肺结节评估与管理:一项混合方法研究
Contemporary Pulmonary Nodule Evaluation and Management in the U.S.: A Mixed Methods Study.
一种文本挖掘工具在早期可切除非小细胞肺癌常规临床数据提取中的验证
Validation of a Text-Mining Tool for Extracting Routine Clinical Care Data in Early-Stage Resectable Non-Small Cell Lung Cancer.
SEZ6 靶向 PET 成像与 α 粒子放射性免疫治疗对小细胞肺癌检测与治疗的有效性研究
SEZ6-Targeted PET Imaging and Alpha-Particle Radioimmunotherapy is Effective for Detection and Treatment of Small Cell Lung Cancer.
7月28日 星期二 · 5 篇
间质性肺病合并肺癌：匹配的病例对照与队列分析
Lung cancer in interstitial lung disease: a matched case-control and cohort analysis.
病灶内工具——但仍偏离目标：对肺癌筛查的警示呼吁
Tool In Lesion- But Still Off Target: A Call of Concern for Lung Cancer Screening.
SGLT2抑制剂与COPD合并2型糖尿病患者肺癌风险降低相关
Reduced Risk of Lung Cancer Associated with Sodium-Glucose Cotransporter-2 Inhibitors in Patients with COPD and Type 2 Diabetes Mellitus.
径向支气管内超声联合电磁导航支气管镜检查：NEBULA研究——一项随机对照试验
The addition of radial endobronchial ultrasound to electromagnetic navigation bronchoscopy: the NEBULA study - a randomised controlled trial.
PD-1阻断后肿瘤浸润浆细胞特征分析揭示肿瘤特异性抗体
Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.
7月27日 星期一 · 2 篇
BACH1在非小细胞肺癌中的临床意义
Clinical Relevance of BACH1 Expression in Non-Small Cell Lung Cancer.
ZC3H18的相分离转录激活LDHA并形成乳酸化介导的正反馈环路以促进肺癌发生
The phase separation of ZC3H18 transcriptionally activates LDHA and forms lactylation-mediated positive feedback loop to promote tumorigenesis of lung cancer.
7月26日 星期日 · 6 篇
基于活检标本预测早期肺腺癌通过气腔扩散的预测模型
Prediction of spread through air spaces with biopsy specimens in early-stage adenocarcinoma of the lung.
EGFR 突变型 NSCLC 脑膜转移个体化管理风险分层模型的开发与验证 (LM-Index)
Development and validation of a risk-stratification model for individualized management of leptomeningeal metastases in EGFR- mutant NSCLC (LM-Index).
气腔播散在多发同步双侧原发性肺癌中的意义:手术队列的预后分析
Spread through air spaces in multiple synchronous bilateral primary lung cancer: prognostic implications in a surgical cohort.
肺类癌/NET G3 的临床病理及预后验证:高分化神经内分泌肿瘤中一个独特亚组的证据
Clinicopathological and prognostic validation of pulmonary carcinoid/NET G3: evidence for a distinct subgroup of well-differentiated neuroendocrine neoplasms.
利用人工智能支持的流程改善急诊科偶发性肺结节的随访
Improving follow-up of incidental pulmonary nodules in the emergency department using an artificial intelligence-supported workflow.
肺癌术中应用Abenacianine进行分子成像的多中心II期临床试验
Phase II Multicenter Clinical Trial of Intraoperative Molecular Imaging with Abenacianine During Lung Cancer Surgery.
7月25日 星期六 · 3 篇
免疫治疗对晚期/转移性肺癌总生存期及医疗费用的影响：一项法国的真实世界研究
Impact of immunotherapy on overall survival and healthcare costs in advanced/metastatic lung cancer: A real-world study in France.
在综合医疗体系中,有乳腺癌个人史的女性发生原发性肺癌的风险及后续治疗方式分析
Risk of Primary Lung Cancer in Women with Personal History of Breast Cancer and Subsequent Treatment Modality in an Integrated Health System.
个性化肿瘤负载单核细胞衍生树突状细胞疫苗联合阿替利珠单抗作为广泛期小细胞肺癌(ES-SCLC)维持治疗:VENEZOLUNG Ib-II 期试验
Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial.
7月24日 星期五 · 4 篇
NF-κB/ALDH1A1 信号通路激活促进非小细胞肺癌对 EGFR-TKI 的非突变型耐药
Activation of the NF-κB/ALDH1A1 signaling promotes non-mutational resistance to EGFR-TKIs in non-small cell lung cancer.
长链非编码 RNA MNX1-AS1 通过阻止 CACYBP 降解介导一碳代谢调控以促进肺癌进展
Long noncoding RNA MNX1-AS1 mediated regulation of one-carbon metabolism by preventing CACYBP degradation to promote lung cancer progression.
N6-甲基腺苷介导的 PAICS 上调通过 integrin-FAK 信号通路促进肺腺癌转移
N6-methyladenosine-mediated upregulation of PAICS promotes lung-adenocarcinoma metastasis via the integrin-FAK signaling.
肺腺癌远处转移的机制与治疗靶点
Mechanisms and therapeutic targets in distant metastasis of lung adenocarcinoma.
7月23日 星期四 · 4 篇
安罗替尼联合派安普利单抗二线治疗 ES-SCLC 的疗效及生物标志物探索：Ⅱ期 ALTER-L041 试验结果
Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial.
面向 NSCLC 临床试验预筛选的安全感知 AI：基于规则、单智能体与多智能体方法的对比概念验证研究
Safety-aware AI for NSCLC trial pre-screening: a comparative proof-of-concept study of rule-based, single-agent, and multi-agent approaches.
缺氧微生态作为EGFR突变型肺癌进展的早期决定因素：对检测、干预及亚型特异性应答的意义
Hypoxic Niche as an Early Determinant of EGFR-Mutant Lung Cancer Progression: Implications for Detection, Intervention, and Subtype-Specific Responses.
双靶向DLL3/CD56的CAR-T细胞中平行4-1BB信号触发适应性增殖与功能持久性以根除小细胞肺癌
Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR-T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer.
7月22日 星期三 · 3 篇
右肺上叶切除术中遇到的一例罕见肺血管连接
An unusual pulmonary vascular connection encountered during right upper lobectomy.
基于 CT 的瘤内异质性评分术前预测肺腺癌淋巴血管侵犯及预后：一项多中心验证与放射基因组学解读
CT-based Intratumoral Heterogeneity Score for Preoperative Prediction of Lymphovascular Invasion and Prognosis in Lung Adenocarcinoma: A Multicenter Validation and Radiogenomic Interpretation.
肺腺癌中一种新型 MYO5C-ALK 融合:alectinib 反应有限而 lorlatinib 获益持久
A novel MYO5C-ALK fusion in lung adenocarcinoma: limited alectinib response and durable lorlatinib benefit.
7月21日 星期二 · 3 篇
用于预测 NSCLC EGFR 突变状态的多任务深度学习模型
Multi-task deep learning model for predicting EGFR mutation status in NSCLC.
非小细胞肺癌靶向治疗试验中设计与结果的吻合度：一项 meta 研究
Design-Outcome Concordance in Targeted-Therapy trials in Non-Small cell lung cancer: a Meta-Research study.
UHRF1 通过促进 FDX1 启动子甲基化抑制肺腺癌中的铜死亡
UHRF1 inhibits cuproptosis in lung adenocarcinoma via promoting FDX1 promoter methylation.
7月20日 星期一 · 2 篇
下一代测序在 NSCLC 同步 EBUS-TBNA 和液体活检中的临床应用价值
Clinical Utility of Next Generation Sequencing in Concurrent EBUS-TBNA and Liquid Biopsies in NSCLC.
COPD 与接受一线 ICI 联合化疗的晚期非小细胞肺癌患者较差生存期相关
COPD is associated with poorer survival in patients with advanced non-small cell lung cancer treated with first-line ICI plus chemotherapy.